BIVALIRUDIN VERSUS HEPARIN MONOTHERAPY IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: AN ANALYSIS OF ACUTE ADVERSE OUTCOMES AND COST

MLA

Georges Ephrem, et al. “Bivalirudin Versus Heparin Monotherapy in Patients with St Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: An Analysis of Acute Adverse Outcomes and Cost.” Journal of the American College of Cardiology, no. 10, p. A66. EBSCOhost, https://doi.org/10.1016/S0735-1097(15)60066-3. Accessed 15 Feb. 2025.

APA

Georges Ephrem, Michael Kim, Jonathan Guenoun, Rajiv Jauhar, & Perwaiz M. Meraj. (n.d.). Bivalirudin Versus Heparin Monotherapy in Patients with St Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: An Analysis of Acute Adverse Outcomes and Cost. Journal of the American College of Cardiology, 10, A66. https://doi.org/10.1016/S0735-1097(15)60066-3

Chicago

Georges Ephrem, Michael Kim, Jonathan Guenoun, Rajiv Jauhar, and Perwaiz M. Meraj. 2025. “Bivalirudin Versus Heparin Monotherapy in Patients with St Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: An Analysis of Acute Adverse Outcomes and Cost.” Journal of the American College of Cardiology, no. 10: A66. Accessed February 15. doi:10.1016/S0735-1097(15)60066-3.